康休(CXO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CXO 康休

退市 01-15 16:00:00 EST

65.60

+0.00

0.00%

最高65.60	最低65.60	成交量0.00
今开65.60	昨收65.60	日振幅0.00%
总市值127.60亿	流通市值126.27亿	总股本1.95亿
成交额0.00	换手率0.00%	流通股本1.92亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CXO","market":"US","secType":"STK","nameCN":"康休","latestPrice":65.6,"timestamp":1610744400000,"preClose":65.6,"halted":4,"volume":0,"delay":0,"changeRate":0,"floatShares":192489259,"shares":194506801,"eps":-52.266872,"marketStatus":"退市","change":0,"latestTime":"01-15 16:00:00 EST","open":65.6,"high":65.6,"low":65.6,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-52.266872,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1790064000000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1186113600000,"exchange":"NYSE","adjPreClose":65.6,"dividendRate":0.011052,"volumeRatio":0},"requestUrl":"/m/hq/s/CXO","defaultTab":"news","newsList":[{"id":"2669139506","title":"医药外包概念盘初走高 昭衍新药（06127）涨6.14% 机构指CXO为医药行业中最亮眼板块之一","url":"https://stock-news.laohu8.com/highlight/detail?id=2669139506","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669139506?lang=zh_cn&edition=full","pubTime":"2026-09-21 10:10","pubTimestamp":1789956632,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股医药外包概念盘初走高，截至发稿，昭衍新药（06127）涨6.14%，药明生物（02269）涨4.97%，金斯瑞生物科技（01548）涨4.47%，维亚生物（01873）涨3.75%，药明康德（02359）涨3.40%，泰格医药（03347）涨2.52%，康龙化成（03759）涨2.64%。中邮证券研究指，2026中报看，CXO行业是医药行业中最亮眼板块之一。数据上看，CDMO龙头、安评及临床CRO是三条景气主线。估值上看，CDMO龙头公司按2027PE仍处于合理区间，CRO环节公司报表仍处修复阶段，新签高毛利订单待转化，因此表观估值较高，但预计随着订单的逐渐周转快速消化。","market":"other","thumbnail":"https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992050","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0052750758.USD","LU0181495838.USD","LU0516422952.EUR","09939","LU0051755006.USD","LU0307460666.USD","LU0516422440.USD","BK1141","06127","BK1589","02359","LU0516422366.SGD","LU0516423091.SGD","BK1610","01548","LU3063872942.SGD","603127","WX","LU1242518857.USD","HK0000320223.HKD","LU0516423174.USD","LU0359202008.SGD","LU0540923850.HKD","LU0029874061.USD","LU0359201612.USD","LU0588546209.SGD","LU2125910500.SGD","LU0348766576.USD","LU0348825331.USD","LU0039217434.USD","03759","BK1161","01873","LU1880383366.USD","LU0456846285.SGD","LU0561508036.HKD","LU2242644610.SGD","HK0000306701.USD","LU0029874905.USD","BK1583","LU1794554557.SGD","03347","02269","KURE","LU0043850808.USD","CXO","BK1515","SG9999002463.SGD","159938","LU0320764599.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668919819","title":"CXO板块上扬 昭衍新药（06127）涨5.64%、金斯瑞生物科技（01548）涨4.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2668919819","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668919819?lang=zh_cn&edition=full","pubTime":"2026-09-18 09:46","pubTimestamp":1789695974,"startTime":"0","endTime":"0","summary":"金吾财讯 | CXO板块上扬，昭衍新药 涨5.64%，金斯瑞生物科技涨4.78%，维亚生物涨2.15%，泰格医药涨1.93%，药明生物涨1.80%，凯莱英涨1.79%，药明康德涨1.01%，百济神州涨0.95%。中信建投近日研报指，CXO是创新药产业链专业化分工的重要载体，也是连接药物研发与商业化生产的关键基础设施。随着内外需改善逐步传导至订单与业绩，CXO有望进入新一轮增长阶段。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/MzQyYjVhODQ3ZWY1M2M1MGY5NWIyMTYzODE1MzIxNzE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MzQyYjVhODQ3ZWY1M2M1MGY5NWIyMTYzODE1MzIxNzE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991930","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0828237510.HKD","BK1521","LU2039709279.SGD","LU0856984785.SGD","LU0516423174.USD","01548","LU0039217434.USD","LU0052750758.USD","02269","603127","02359","LU1880383366.USD","LU0128522744.USD","WX","LU0051755006.USD","LU0181495838.USD","BK0216","LU1242518931.SGD","LU0029874905.USD","SG9999002562.SGD","LU1251922891.USD","KURE","IE00B0JY6N72.USD","06160","06127","LU0029874061.USD","CXO","BK1161","LU0320764599.SGD","LU0348827113.USD","LU3063872942.SGD","LU0634319403.HKD","03347","BK1588","06821","LU0228659784.USD","LU0359202008.SGD","LU0469268626.HKD","LU0561508036.HKD","LU0588546209.SGD","LU1688375341.USD","01873","LU0320764243.SGD","LU1719994722.HKD","LU2242644610.SGD","LU0348735423.USD","LU1242518857.USD","LU0456846285.SGD","BK1610","LU0348825331.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668930626","title":"港股异动 | CRO概念股涨幅居前 AIDD利好催化密集 CXO板块景气度明确上行","url":"https://stock-news.laohu8.com/highlight/detail?id=2668930626","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668930626?lang=zh_cn&edition=full","pubTime":"2026-09-17 10:08","pubTimestamp":1789610899,"startTime":"0","endTime":"0","summary":"消息面上，近期，AIDD利好催化密集。招商证券近期研报指出，CXO板块景气度明确上行。今年上半年国内CXO板块营收、归母净利润同比分别增长24.5%、52.7%，利润增速接近上一轮周期高点；在手订单与新签订单全面回暖，龙头上调全年指引。此外，AI制药有望重塑医药研发业态，提升药物研发效率，板块亦将受益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1497225.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK1583","HK0000306701.USD","BK1191","WX","HK0000306685.HKD","01548","06821","BK1576","KCAI","02315","01873","BK4588","BK1161","CXO","BK1141","HK0000320264.USD","VXUS","HK0000320223.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667218626","title":"生物制品及CXO行业集体与投资者互动 企业“出海”进阶 从产品输出迈向能力输出","url":"https://stock-news.laohu8.com/highlight/detail?id=2667218626","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667218626?lang=zh_cn&edition=full","pubTime":"2026-09-16 00:16","pubTimestamp":1789488960,"startTime":"0","endTime":"0","summary":"9月15日，科创板细分行业集体业绩说明会之生物制品及CXO（医药外包服务）行业集体业绩说明会召开，多家上市公司高管出席。从投资者互动的情况中可知，对于生物制品及CXO行业上市公司，关注的主要事项集中在“出海”、研发等方面。在互动过程中，相关公司高管进行了详细解答。在相关上市公司的半年报和互动过程中，“加大海外市场拓展力度”等信息被频繁提及。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609163875135164.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609163875135164.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["CXO","WX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667165628","title":"中信建投：内外需改善逐步传导订单与业绩 CXO有望进入新一轮增长阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2667165628","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667165628?lang=zh_cn&edition=full","pubTime":"2026-09-14 15:50","pubTimestamp":1789372227,"startTime":"0","endTime":"0","summary":"随着内外需改善逐步传导至订单与业绩，CXO有望进入新一轮增长阶段。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495591.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["601066","BK0276","WX","CXO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666513175","title":"东北证券：创新药BD和商业化持续兑现 CXO超预期，传统板块筑底拐点","url":"https://stock-news.laohu8.com/highlight/detail?id=2666513175","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666513175?lang=zh_cn&edition=full","pubTime":"2026-09-10 09:55","pubTimestamp":1789005326,"startTime":"0","endTime":"0","summary":"东北证券主要观点如下：创新药板块：海外创新药产业高景气延续，国产药企有望承接红利Pharma依托多元路径实现营收稳健增长，Biotech凭借BD和商业化释放业绩弹性。多家创新药企业2026H1业绩超预期增长，这与CXO板块公司的半年度业绩相印证，进一步确认了板块的中期产业趋势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494239.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","000686","BK1161","MEDX","BK0276","IBBQ","LNGR","BK1574","BK0183","CXO","WX","06978","159992","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665934734","title":"分拆上市成利好？金斯瑞大反攻，飙升逾12%！华宝基金港股通医疗ETF（159137）标的指数涨近2%，CXO全线提振","url":"https://stock-news.laohu8.com/highlight/detail?id=2665934734","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665934734?lang=zh_cn&edition=full","pubTime":"2026-09-08 14:06","pubTimestamp":1788847560,"startTime":"0","endTime":"0","summary":"CXO概念集体走强，金斯瑞生物科技飙升逾12%，百奥赛图-B涨超9%，泰格医药、凯莱英涨超7%，药明合联涨超4%。港股通医疗ETF华宝标的指数CXO含量超50%，午后涨近2%！全链布局创新药，关注两大T+0交易利器：港股通医疗ETF华宝：被动跟踪港股通医疗主题指数，重仓创新药产业链，50%CXO+20%创新药，其中药明系占比超38%。港股通创新药ETF华宝：被动跟踪恒生港股通创新药精选指数，100%布局创新药研发类公司，7成仓位押注研发龙头。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-08/doc-inirayqy9498188.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["SPIT","159137","WX","ACTV","CXO","159828","CSD","FLHK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665319763","title":"昊海生科：关于参加科创板2026年半年度生物制品及CXO行业集体业绩说明会的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2665319763","media":"证券日报网","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665319763?lang=zh_cn&edition=full","pubTime":"2026-09-07 18:43","pubTimestamp":1788777780,"startTime":"0","endTime":"0","summary":"证券日报网讯9月7日，昊海生科发布公告称，公司计划于2026年9月15日15：00-17：00参加由上海证券交易所主办的科创板2026年半年度生物制品及CXO行业集体业绩说明会。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/hk/2026-09-07/doc-iniqyzxu6392948.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-09-07/doc-iniqyzxu6392948.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","688366","BK0251","KSTR","CXO","WX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665369630","title":"创新药三大指数上涨、ETF吸金，CXO及科研服务呈高景气度","url":"https://stock-news.laohu8.com/highlight/detail?id=2665369630","media":"环球网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665369630?lang=zh_cn&edition=full","pubTime":"2026-09-06 09:57","pubTimestamp":1788659820,"startTime":"0","endTime":"0","summary":"H股创新药指数2026上半年收入同比增长17.91%、归母净利润同比增长60.94%、扣非归母净利润同比增长30.73%。银河证券分析称，上半年行业利润增长显著快于收入，主要系创新药商业化收入及对外授权收入增加，高毛利业务占比大幅提升，同时CXO和科研服务呈高景气度，订单增长驱动前期产能建设和人员储备充分利用，摊薄固定成本并推动利润增长。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-09-06/doc-iniqvzvc0193188.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["MEDX","BK1574","FDN","WX","06978","BK1161","IBBQ","BK4550","159992","LNGR","CXO","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664855519","title":"医疗器械迎业绩拐点？512170成功收红！AI4S带火港股CXO，金斯瑞涨超7%！港股通医疗ETF华宝逆市上扬","url":"https://stock-news.laohu8.com/highlight/detail?id=2664855519","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664855519?lang=zh_cn&edition=full","pubTime":"2026-09-01 19:12","pubTimestamp":1788261120,"startTime":"0","endTime":"0","summary":"9月1日，A股港股医疗板块逆市表现，医疗ETF华宝、港股通医疗ETF华宝等相关品种热度再升温。医疗器械方面，英科医疗上半年营收、净利双增，迈瑞医疗利润降幅显著收窄至5.4%，联影医疗营收同比增长17%。中信建投研报指出，医疗器械行业迎来业绩修复拐点，2026Q2归母净利润实现四年首正增长，板块整体企稳回升。聚焦医疗器械+医疗服务，CXO含量超30%，兼顾脑机接口、AI医疗。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-01/doc-iniqipis4811448.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1583","MDEV","LNGR","CXO","GDOC","BK4585","KCAI","MEDX","512170","HART","PTH","159883","LGHT","IEIH","AGNG","BK1574","BK4588","VXUS","WX","09996","RSPH","FLHK","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664896628","title":"招商证券： 需求释放 CXO板块景气度明确上行","url":"https://stock-news.laohu8.com/highlight/detail?id=2664896628","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664896628?lang=zh_cn&edition=full","pubTime":"2026-09-01 08:09","pubTimestamp":1788221376,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0028","CXO","06099","BK0012","BK1147","BK1564","BK0183","WX","BK0188","BK0276","600999","BK0010"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662766810","title":"CXO今天也是支棱起来了","url":"https://stock-news.laohu8.com/highlight/detail?id=2662766810","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662766810?lang=zh_cn&edition=full","pubTime":"2026-08-26 09:11","pubTimestamp":1787706660,"startTime":"0","endTime":"0","summary":"来源：硬核姬老板MACD金叉信号形成，这些股涨势不错！","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-26/doc-inipqxha2247730.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["CXO","WX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662731118","title":"中报再点火，CXO全线爆发！药明合联、凯莱英绩后狂飙，港股通医疗ETF（159137）爆量大涨，成交额激增超300%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662731118","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662731118?lang=zh_cn&edition=full","pubTime":"2026-08-25 19:41","pubTimestamp":1787658060,"startTime":"0","endTime":"0","summary":"CXO含量超50%的港股通医疗ETF华宝全天单边上行，日线强势“阳包阴”！24日，药明合联、凯莱英双双发布2026年中报，上半年经调整归母净利润均实现同比两位数增长，增速分别为37.4%、12.9%。药明合联上半年未完成总订单达22亿美元，同比大幅增长62.2%；凯莱英公司在手订单总额16.73亿美元，较去年同期增长53.77%，新签订单同比增长54.59%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-25/doc-inipprnk9691167.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["FLHK","BK0132","BK0239","LU2488822045.USD","06821","BK1141","CXO","002821","SG9999014674.SGD","WX","159137","LU1328615791.USD","159828","BK1191","02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662004362","title":"港股异动 | CRO概念股涨幅居前 海外CXO业绩普遍超预期 机构指全球需求复苏确认","url":"https://stock-news.laohu8.com/highlight/detail?id=2662004362","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662004362?lang=zh_cn&edition=full","pubTime":"2026-08-25 10:20","pubTimestamp":1787624451,"startTime":"0","endTime":"0","summary":"消息面上，IQVIA、Medpace、Lonza、三星生物等海外CXO龙头业绩密集披露，订单端强势反转，多家上调全年指引。湘财证券认为，近期CXO整体表现亮眼是全球医药融资回暖下产业基本面持续向好的全球性的趋势，中国CXO相关公司具备工程师红利将充分享受产业红利，在全球产业向好的趋势下持续性预计将较强。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1484814.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0327786744.USD","LU2039709279.SGD","01548","LU0140636845.USD","LU1794554557.SGD","LU0348825331.USD","03347","BK1521","LU0128526141.USD","LU0456827905.SGD","LU0516422440.USD","LU1242518931.SGD","KCAI","LU0708995583.HKD","LU0979878070.USD","WX","BK4588","HK0000320223.HKD","06821","LU0823426308.USD","BK1610","VXUS","LU0051755006.USD","LU0359201612.USD","BK4585","CXO","LU0516423174.USD","HK0000320264.USD","LU0359202008.SGD","LU1880383366.USD","LU0307460666.USD","LU0181495838.USD","BK1576","LU0572944931.SGD","LU0856984785.SGD","LU1688375341.USD","LU0029874061.USD","LU0417516902.SGD","LU0052750758.USD","KURE","LU0417516738.SGD","BK1583","LU0516422952.EUR","LU0823426480.USD","LU3063872942.SGD","LU0320764599.SGD","LU1242518857.USD","LU0456846285.SGD","02269","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662200320","title":"医药外包概念盘初普升 凯莱英（06821）涨6.21% 机构指CXO行业景气上行逻辑不断夯实","url":"https://stock-news.laohu8.com/highlight/detail?id=2662200320","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662200320?lang=zh_cn&edition=full","pubTime":"2026-08-25 09:57","pubTimestamp":1787623040,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股医药外包概念盘初普升，截至发稿，凯莱英 涨6.21%，金斯瑞生物科技涨4.78%，药明生物涨2.22%，维亚生物涨1.67%，泰格医药涨1.05%。消息面上，国金证券表示，CXO行业景气度持续向上，全球生物医药投融资回暖带动创新药研发投入提速，海内外龙头订单与业绩逐步兑现，行业景气上行逻辑不断夯实。头部CXO企业也主动融合AI能力，迭代实验与生产体系。在传统创新药需求叠加AI制药增量的共振之下，行业中长期成长空间进一步打开。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1989237","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0708995583.HKD","HK0000320264.USD","02269","LU1242518931.SGD","LU0979878070.USD","LU0359201612.USD","LU0456827905.SGD","LU0516422366.SGD","LU0819121731.USD","03347","SG9999002463.SGD","01548","KURE","LU0359202008.SGD","159938","BK1515","09939","LU1242518857.USD","LU1794554557.SGD","BK1610","BK0239","LU1720050803.USD","HK0000320223.HKD","LU1880383366.USD","BK1161","CXO","LU0140636845.USD","LU0326950275.SGD","LU0348825331.USD","LU0516422952.EUR","06821","BK1191","002821","LU0856984785.SGD","LU0029874061.USD","LU0823426308.USD","BK0132","01873","LU0181495838.USD","LU0051755006.USD","LU0516423091.SGD","SG9999002562.SGD","LU0307460666.USD","BK1589","HK0000306685.HKD","LU0456846285.SGD","LU0516422440.USD","LU0052750758.USD","LU0039217434.USD","WX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661275244","title":"创新药突然哑火，什么原因？华宝基金港股通创新药ETF再失半年线，CXO龙头尽墨，机构:四季度继续看好医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2661275244","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661275244?lang=zh_cn&edition=full","pubTime":"2026-08-24 19:48","pubTimestamp":1787572080,"startTime":"0","endTime":"0","summary":"8月24日，港股深度调整，近期热度较高的医药板块同步走低。100%创新药研发标的——港股通创新药ETF华宝日线连阴，收于半年线下方，全天振幅3.44%，成交3.18亿元。值得一提的是，截至上周，159137在CXO带动连续5周收涨。全链布局创新药，关注两大T+0利器：港股通创新药ETF华宝：被动跟踪恒生港股通创新药精选指数，100%布局创新药研发类公司，7成仓位押注研发龙头。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-24/doc-inipmnps2837356.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09939","159316","WX","BK1515","159938","LNGR","MEDX","159992","CXO","IBBQ","FLHK","BK1574","06978","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661219033","title":"天风·医药 | AI4S加速科研范式变革，中国CXO有望迎来产业与估值共振","url":"https://stock-news.laohu8.com/highlight/detail?id=2661219033","media":"天风研究","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661219033?lang=zh_cn&edition=full","pubTime":"2026-08-22 17:00","pubTimestamp":1787389200,"startTime":"0","endTime":"0","summary":"AI制药从模型创新走向干湿闭环，上游科研服务率先迎来需求放量。头部化+新分子+全球化构筑竞争力，CXO板块有望迎来业绩与估值共振。中国CXO全球竞争力持续提升，凭借规模化生产及成本效率优势，全球市场份额仍具提升空间。我们看好创新药融资回暖、AI4S增量需求及全球外包率提升共同驱动中国CXO景气修复，重点关注具备新分子技术平台、干湿闭环能力及全球化产能布局的头部企业。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["research"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzAwMzIzNzcwMg==&mid=2649153755&idx=5&sn=127ad91cbcf60f400d074876ef23f90d&chksm=828fc6fc1429d4147bb3a6df8c3bcd3eef4a76c32b15ef7d913857d6527fd0b1ff368107047f&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["CXO","WX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660419923","title":"CXO概念有支撑 凯莱英（06821）涨2.27% 金斯瑞生物科技（01548）涨2.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660419923","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660419923?lang=zh_cn&edition=full","pubTime":"2026-08-19 10:53","pubTimestamp":1787108028,"startTime":"0","endTime":"0","summary":"金吾财讯 | CCXO概念有支撑，凯莱英 涨2.27%、金斯瑞生物科技涨2.41%、百济神州涨0.63%、方达控股涨0.79%、药明生物涨0.04%爱建证券表示，2026年初以来医药板块的持续回调与行业基本面、产业趋势发生背离，近期众多上市公司推出现金回购和增持方案，反映出对产业未来发展的充足信心，CXO、创新药及相关产业链已率先发力反弹，医药板块中长期布局良机已至。同时，该机构看好高景气CXO、器械出海、脑机接口、AI+医疗等投资机会。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/ODBhOTU0MzI3NjMwOTM5MjE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ODBhOTU0MzI3NjMwOTM5MjE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1988641","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2328871848.SGD","SG9999002463.SGD","LU0348825331.USD","BK1191","LU0359202008.SGD","LU0181495838.USD","LU1720050803.USD","BK1589","LU0359201612.USD","LU0588546209.SGD","LU1969619763.USD","LU1770034418.SGD","06821","CXO","LU0819121731.USD","06160","LU0516422366.SGD","LU0417516902.SGD","HK0000320223.HKD","HK0000306685.HKD","LU1688375341.USD","BK0239","002821","LU1719994722.HKD","LU0516422440.USD","LU3063872942.SGD","LU0039217434.USD","LU0516423091.SGD","LU0128526141.USD","01521","LU0828237510.HKD","LU0052750758.USD","LU0417516738.SGD","LU0140636845.USD","LU0228659784.USD","01548","LU0043850808.USD","BK1141","LU0320764599.SGD","WX","LU0708995583.HKD","BK1576","LU1242518931.SGD","LU0456827905.SGD","BK1500","KURE","LU0572944931.SGD","BK1610","BK1588","02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660490014","title":"国产创新药迎三重业绩拐点 CXO龙头利润与订单同步创出历史新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2660490014","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660490014?lang=zh_cn&edition=full","pubTime":"2026-08-19 07:25","pubTimestamp":1787095509,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["CXO","IBBQ","WX","LNGR","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660464424","title":"CXO开启主升浪，药明系、金斯瑞、康龙等集体突破！华宝基金港股通医疗ETF创5个月收盘新高，医疗ETF8天7阳","url":"https://stock-news.laohu8.com/highlight/detail?id=2660464424","media":"新浪基金","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660464424?lang=zh_cn&edition=full","pubTime":"2026-08-18 19:45","pubTimestamp":1787053500,"startTime":"0","endTime":"0","summary":"8月18日，CXO强者恒强，继续领涨医疗板块！场内高CXO含量ETF继续上行，港股通医疗ETF华宝标的指数CXO含量全市场第一，场内价格续涨1.25%创5个月收盘新高！全市场规模最大医疗ETF华宝CXO含量超30%，斩获8天7阳。药明康德半年度净利润历史首次突破百亿元大关，并大幅上调全年指引；康龙化成Q2收入和经调利润分别同比增长19.38%和22.3%；昭衍新药上半年归母净利润同比预增884.9%至1377.4%。其中药明系占比超38%。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-18/doc-inintxxh8569801.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["CXO","WX","159828","FLHK"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.concho.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.0034},{"period":"1month","weight":-0.0096},{"period":"3month","weight":0.02},{"period":"6month","weight":0.1744},{"period":"1year","weight":0.1501},{"period":"ytd","weight":0.117}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Concho Resources Inc.成立于2006年2月22日，是一家于2006年2月在特拉华州注册成立的公司，是一家独立的石油和天然气公司，从事石油和天然气资产的收购、开发、勘探和生产。","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":0.054246},{"month":2,"riseRate":0.384615,"avgChangeRate":-0.002949},{"month":3,"riseRate":0.692308,"avgChangeRate":0.024071},{"month":4,"riseRate":0.769231,"avgChangeRate":0.069872},{"month":5,"riseRate":0.384615,"avgChangeRate":-0.030229},{"month":6,"riseRate":0.461538,"avgChangeRate":0.004495},{"month":7,"riseRate":0.692308,"avgChangeRate":0.012949},{"month":8,"riseRate":0.461538,"avgChangeRate":-0.02419},{"month":9,"riseRate":0.571429,"avgChangeRate":0.015298},{"month":10,"riseRate":0.5,"avgChangeRate":0.017047},{"month":11,"riseRate":0.571429,"avgChangeRate":0.047858},{"month":12,"riseRate":0.642857,"avgChangeRate":0.007299}],"exchange":"NYSE","name":"康休","nameEN":"Concho Resources"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康休(CXO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康休(CXO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康休,CXO,康休股票,康休股票老虎,康休股票老虎国际,康休行情,康休股票行情,康休股价,康休股市,康休股票价格,康休股票交易,康休股票购买,康休股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康休(CXO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康休(CXO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}